core assay list 2011
DESCRIPTION
In Vitro Cell Based AssayTRANSCRIPT
IN-VITRO CELL BASED ASSAY- CORE ASSAY LIST 2011
R & D Centre: Plot # 5B, 19th K.M Stone, Hosur Road, Bangalore – 560 100, India. Tel: 91-080-7832265, 7833092, 7834872, Fax: 91-080-7834369, E-mail: [email protected]
CORE ASSAY LIST 2011 THERAPEUTIC AREA – IMMUNOMODULATION
REF# Project Type Assay Principle
Turn Around
Time
Minimum Compound Required
Standard Format
CA01 Cell Proliferation
Test model: Determine effect of mitogens/inhibitors on cell proliferation in murine splenocytes/Human PBMC. Useful for lead optimization of proliferation/ anti-proliferation compounds. Assay format: Incubations in 48-well plates. MTT read out. Data format: WordTM report with data available in an ExcelTM file.
4 Weeks 10 mg Up to 3 compounds at 5 concentrations tested in quadruplicate
CA02 Mediator release
Test model: Determine effect of compounds on (un-stimulated) Nitric Oxide release from murine macrophages. Useful for lead optimization for pro-inflammatory compounds and potency determination. Assay format: Incubations in 96-well plates. Colorimetric. Data format: WordTM report with data available in an ExcelTM file.
4 Weeks 10 mg Up to 4 compounds at 5 concentrations tested in triplicate
CA03 Mediator release
Test model: Determine effect of compounds on (stimulated) cytokine release (IL-2) from murine splenocytes. Useful for lead optimization for pro-inflammatory compounds and potency determination. Assay format: Incubations in 48-well plates. ELISA. Data format: WordTM report with data available in an ExcelTM file.
4 Weeks 10 mg Up to 3 compounds at 5 concentrations tested in quadruplicate
CA04 Mediator release
Test model: Determine effect of compounds on (stimulated) cytokine release (IL-3) from murine splenocytes. Useful for lead optimization for pro-inflammatory compounds and potency determination. Assay format: Incubations in 48-well plates. ELISA. Data format: WordTM report with data available in an ExcelTM file.
4 Weeks 10 mg Up to 3 compounds at 5 concentrations tested in quadruplicate
R & D Centre: Plot # 5B, 19th K.M Stone, Hosur Road, Bangalore – 560 100, India. Tel: 91-080-7832265, 7833092, 7834872, Fax: 91-080-7834369, E-mail: [email protected]
THERAPEUTIC AREA – IMMUNOMODULATION
REF# Project Type Assay Principle
Turn Around
Time
Minimum Compound Required
Standard Format
CA05 Mediator release
Test model: Determine effect of compounds on (stimulated) cytokine release (IL-4) from murine splenocytes. Useful for lead optimization for Anti-inflammatory compounds and potency determination. Assay format: Incubations in 48-well plates. ELISA. Data format: WordTM report with data available in an ExcelTM file.
4 Weeks 10 mg Up to 3 compounds at 5 concentrations tested in quadruplicate
CA06 Mediator release
Test model: Determine effect of compounds on (stimulated) cytokine release (IL-5) from murine splenocytes. Useful for lead optimization for pro-inflammatory compounds and potency determination. Assay format: Incubations in 48-well plates. ELISA. Data format: WordTM report with data available in an ExcelTM file.
4 Weeks 10 mg Up to 3 compounds at 5 concentrations tested in quadruplicate
CA07 Mediator release
Test model: Determine effect of compounds on (stimulated) cytokine release (IL-6) from murine splenocytes. Useful for lead optimization for Anti-inflammatory compounds and potency determination. Assay format: Incubations in 48-well plates. ELISA. Data format: WordTM report with data available in an ExcelTM file.
4 Weeks 10 mg Up to 3 compounds at 5 concentrations tested in quadruplicate
CA08 Mediator release
Test model: Determine effect of compounds on (stimulated) cytokine release (IL-10) from murine splenocytes. Useful for lead optimization for Anti-inflammatory compounds and potency determination. Assay format: Incubations in 48-well plates. ELISA. Data format: WordTM report with data available in an ExcelTM file.
4 Weeks 10 mg Up to 3 compounds at 5 concentrations tested in quadruplicate
R & D Centre: Plot # 5B, 19th K.M Stone, Hosur Road, Bangalore – 560 100, India. Tel: 91-080-7832265, 7833092, 7834872, Fax: 91-080-7834369, E-mail: [email protected]
THERAPEUTIC AREA – IMMUNOMODULATION
REF# Project Type Assay Principle
Turn Around
Time
Minimum Compound Required
Standard Format
CA09 Mediator release
Test model: Determine effect of compounds on (stimulated) cytokine release (IL-12) from murine splenocytes. Useful for lead optimization for Anti-inflammatory compounds and potency determination. Assay format: Incubations in 48-well plates. ELISA. Data format: WordTM report with data available in an ExcelTM file.
4 Weeks 10 mg Up to 3 compounds at 5 concentrations tested in quadruplicate
CA10 Mediator release
Test model: Determine effect of compounds on (stimulated) cytokine release (IFN-γ) from murine splenocytes. Useful for lead optimization for pro-inflammatory compounds and potency determination. Assay format: Incubations in 48-well plates. ELISA. Data format: WordTM report with data available in an ExcelTM file.
4 Weeks 10 mg Up to 3 compounds at 5 concentrations tested in quadruplicate
R & D Centre: Plot # 5B, 19th K.M Stone, Hosur Road, Bangalore – 560 100, India. Tel: 91-080-7832265, 7833092, 7834872, Fax: 91-080-7834369, E-mail: [email protected]
THERAPEUTIC AREA – ALLERGY/PAIN AND INFLAMMATION
REF# Project Type Assay Principle
Turn Around
Time
Minimum Compound Required
Standard Format
CA11 Mediator release
Test model: Determine effect of compounds on (stimulated) Nitric Oxide release from murine macrophages. Useful for lead optimization for Anti-inflammatory compounds and potency determination. Assay format: Incubations in 96-well plates. Colorimetric. Data format: WordTM report with data available in an ExcelTM file.
4 Weeks 10 mg Up to 4 compounds at 5 concentrations tested in triplicate
CA12 Mediator release
Test model: Determine effect of compounds on (stimulated) Prostaglandin release (PGE2) from murine macrophages. Useful for lead optimization for Anti-inflammatory compounds and potency determination. Assay format: Incubations in 96-well plates. HTRF. Data format: WordTM report with data available in an ExcelTM file.
4 Weeks 10 mg Up to 4 compounds at 5 concentrations tested in triplicate
CA13 Mediator release
Test model: Determine effect of compounds on (stimulated) Thromboxane release (TXB2) from Human pro-myelocytic leukemia cells. Useful for lead optimization for Anti-inflammatory compounds and potency determination. Assay format: Incubations in 96-well plates. ELISA. Data format: WordTM report with data available in an ExcelTM file.
4 Weeks 10 mg Up to 4 compounds at 5 concentrations tested in triplicate
CA14 Mediator release
Test model: Determine effect of compounds on (stimulated) Leukotriene release (LTB4) from Human pro-myelocytic leukemia cells. Useful for lead optimization for Anti-inflammatory compounds and potency determination. Assay format: Incubations in 96-well plates. HTRF. Data format: WordTM report with data available in an ExcelTM file.
4 Weeks 10 mg Up to 4 compounds at 5 concentrations tested in triplicate
R & D Centre: Plot # 5B, 19th K.M Stone, Hosur Road, Bangalore – 560 100, India. Tel: 91-080-7832265, 7833092, 7834872, Fax: 91-080-7834369, E-mail: [email protected]
THERAPEUTIC AREA – ALLERGY/PAIN AND INFLAMMATION
REF# Project Type Assay Principle
Turn Around
Time
Minimum Compound Required
Standard Format
CA15 Mediator release
Test model: Determine effect of compounds on (stimulated) cytokine release (IL-1β) from murine macrophages. Useful for lead optimization for Anti-inflammatory compounds and potency determination. Assay format: Incubations in 96-well plates. ELISA. Data format: WordTM report with data available in an ExcelTM file.
4 Weeks 10 mg Up to 4 compounds at 5 concentrations tested in triplicate
CA16 Mediator release
Test model: Determine effect of compounds on (stimulated) Histamine release from rat basophilic leukemia cells. Useful for lead optimization for Anti-allergic compounds and potency determination. Assay format: Incubations in 96-well plates. HTRF. Data format: WordTM report with data available in an ExcelTM file.
4 Weeks 10 mg Up to 4 compounds at 5 concentrations tested in triplicate
CA17 Mediator release
Test model: Determine effect of compounds on (stimulated) cytokine release (MCP-1) from murine peritoneal macrophages. Useful for lead optimization for Anti-inflammatory compounds and potency determination. Assay format: Incubations in 96-well plates. ELISA. Data format: WordTM report with data available in an ExcelTM file.
4 Weeks 10 mg Up to 4 compounds at 5 concentrations tested in triplicate
R & D Centre: Plot # 5B, 19th K.M Stone, Hosur Road, Bangalore – 560 100, India. Tel: 91-080-7832265, 7833092, 7834872, Fax: 91-080-7834369, E-mail: [email protected]
THERAPEUTIC AREA – IN VITRO TOXICITY- HEPATOPROTECTION
REF# Project Type Assay Principle
Turn Around
Time
Minimum Compound Required
Standard Format
CA18 In vitro Toxicity
Test model: Measurement of compound toxicity in hepatocytes against t-BH using viability (MTT) endpoints. Assess compound safety before proceeding to clinical development. Assay format: Incubations in 96-well plates. In vitro toxicity profiling. Data format: Word™ report with data available in an Excel™ file.
4 Weeks 10 mg Up to 4 compounds at 5 concentrations tested in triplicate
CA19 In vitro Toxicity
Test model: Measurement of compound toxicity in hepatocytes against diazinon (OPC) using viability (MTT) endpoints. Assess compound safety before proceeding to clinical development. Assay format: Incubations in 96-well plates. In vitro toxicity profiling. Data format: Word™ report with data available in an Excel™ file.
4 Weeks 10 mg Up to 4 compounds at 5 concentrations tested in triplicate
CA19 In vitro Toxicity
Test model: Measurement of compound toxicity in hepatocytes against Aldrin (OC) using viability (MTT) endpoints. Assess compound safety before proceeding to clinical development. Assay format: Incubations in 96-well plates. In vitro toxicity profiling. Data format: Word™ report with data available in an Excel™ file.
4 Weeks 10 mg Up to 4 compounds at 5 concentrations tested in triplicate
CA20 In vitro Toxicity
Test model: Measurement of compound toxicity in hepatocytes against Aflatoxin (AFB1) using viability (MTT) endpoints. Assess compound safety before proceeding to clinical development. Assay format: Incubations in 96-well plates. In vitro toxicity profiling. Data format: Word™ report with data available in an Excel™ file.
4 Weeks 10 mg Up to 4 compounds at 5 concentrations tested in triplicate
R & D Centre: Plot # 5B, 19th K.M Stone, Hosur Road, Bangalore – 560 100, India. Tel: 91-080-7832265, 7833092, 7834872, Fax: 91-080-7834369, E-mail: [email protected]
THERAPEUTIC AREA – IN VITRO TOXICITY- HEPATOPROTECTION
REF# Project Type Assay Principle
Turn Around
Time
Minimum Compound Required
Standard Format
CA21 In vitro Toxicity
Test model: Measurement of compound toxicity in hepatocytes against Galactosamine using viability (MTT) endpoints. Assess compound safety before proceeding to clinical development. Assay format: Incubations in 96-well plates. In vitro toxicity profiling. Data format: Word™ report with data available in an Excel™ file.
4 Weeks 10 mg Up to 4 compounds at 5 concentrations tested in triplicate
THERAPEUTIC AREA – COSMETOLOGY
REF# Project Type Assay Principle
Turn Around
Time
Minimum Compound Required
Standard Format
CA22 Anti-wrinkle
Test model: Determine effect of compounds on (un-stimulated) collagen release from primary human dermal fibroblast. Useful for lead optimization for cosmetology ingredient. Assay format: Incubations in 96-well plates. Colorimetric. Data format: WordTM report with data available in an ExcelTM file.
4 Weeks 10 mg Up to 4 compounds at 5 concentrations tested in triplicate
CA23 Skin whitening
Test model: Determine effect of compounds on (un-stimulated) Melanin release from mouse melanoma cells. Useful for lead optimization for cosmetology ingredient. Assay format: Incubations in 96-well plates. Colorimetric. Data format: WordTM report with data available in an ExcelTM file.
4 Weeks 10 mg Up to 4 compounds at 5 concentrations tested in triplicate
R & D Centre: Plot # 5B, 19th K.M Stone, Hosur Road, Bangalore – 560 100, India. Tel: 91-080-7832265, 7833092, 7834872, Fax: 91-080-7834369, E-mail: [email protected]
THERAPEUTIC AREA – DIABETES/OBESITY
REF# Project Type Assay Principle Turn
Around Time
Minimum Compound Required
Standard Format
CA24 GSIS Assay
Test Model: Measurement of induction of glucose stimulated Insulin secretion in rat insulinoma cells. This approach is useful for assessing the effectiveness of compounds under development for the treatment of type 1 diabetes. Assay Format: Incubations in 96-well plates. HTRF. Data Format: WordTM report with data available in an ExcelTM file.
4 Weeks 10 mg Up to 4 compounds at 5 concentrations tested in triplicate
CA25
Lipid Metabolism Assays (Adipogenesis)
Test model: Determine effect of compounds on (stimulated) Adipocyte differentiation in Mouse embryonic fibroblast . Useful for lead optimization for inhibitors of adipogenesis. Assay format: Incubations in 96-well plates. Colorimetric. Data format: WordTM report with data available in an ExcelTM file.
4 Weeks 10 mg Up to 4 compounds at 5 concentrations tested in triplicate
CA26
Lipid Metabolism Assays (Adipolysis)
Test model: Determine effect of compounds on (stimulated) glycerol release in Mouse embryonic fibroblast . Useful for loead identification for inhibitors of adipolysis. Assay format: Incubations in 96-well plates. Colorimetric. Data format: WordTM report with data available in an ExcelTM file.
4 Weeks 10 mg Up to 4 compounds at 5 concentrations tested in triplicate
R & D Centre: Plot # 5B, 19th K.M Stone, Hosur Road, Bangalore – 560 100, India. Tel: 91-080-7832265, 7833092, 7834872, Fax: 91-080-7834369, E-mail: [email protected]
THERAPEUTIC AREA – ONCOLOGY
REF# Project Type Assay Principle Turn
Around Time
Minimum Compound Required
Standard Format
CA27 Anti proliferative assay
Test Model: Determine effect of compounds on cell proliferation in human breast adenocarcinoma cells. Useful for lead optimization of anti-cancer compound screening. Assay Format: Incubations in 96-well plates. Colorimetric. Data Format: WordTM report with data available in an ExcelTM file.
4 Weeks 10 mg Up to 4 compounds at 5 concentrations tested in triplicate
THERAPEUTIC AREA – GENERAL HEALTH/ HEART DISEASE
REF# Project Type Assay Principle Turn
Around Time
Minimum Compound Required
Standard Format
CA28 Antioxidant assay
Test Model: Determine the cellular antioxidant potential of compounds in Human hepatocellular liver carcinoma cells. Useful cost-effective method to evaluate the antioxidant activity of foods, dietary supplements, phytochemicals and extracts.. Assay Format: Incubations in 96-well plates. Colorimetric. Data Format: WordTM report with data available in an ExcelTM file.
4 Weeks 10 mg Up to 4 compounds at 5 concentrations tested in triplicate
R & D Centre: Plot # 5B, 19th K.M Stone, Hosur Road, Bangalore – 560 100, India. Tel: 91-080-7832265, 7833092, 7834872, Fax: 91-080-7834369, E-mail: [email protected]
THERAPEUTIC AREA – IN VITRO GENOTOXICITY
REF# Project Type Assay Principle Turn
Around Time
Minimum Compound Required
Standard Format
CA29 Mutagenesis assay
Test Model:. Determine the mutageneic potential of compounds using 5 starins of S.Typhimurium with and without S9 fractions. Quick assay to estimate the carcinogenic potential of a compound Assay Format: Incubations in 384-well plates. Hightroughput. Data Format: WordTM report with data available in an ExcelTM file.
4 Weeks 10 mg Up to 1 compounds at 6 concentrations tested in duplicate.
CA30 Mutagenesis assay
Test model: Determine effect of compounds on the formation of small membrane bound DNA fragments i.e. micronuclei in the cytoplasm of interphase cells using Chinese hamster cells. Useful for early identification of compounds likely to exhibit genotoxic liability. Assay format: Incubations in 90mm petri plates. Manual. Data format: WordTM report with data available in an ExcelTM file.
15 Weeks 10 mg Up to 1 compounds at 3 concentrations tested in duplicate.
CA31 Cytogenetic Assays
Test model: Determine effect of compounds on induction of structural changes in chromosomes using Chinese hamster cells. Useful to identify agents that cause structural chromosome aberration in cultured mammalian cells. Assay format: Incubations in 90mm petri plates. Manual. Data format: WordTM report with data available in an ExcelTM file.
15 Weeks 10 mg Up to 1 compounds at 3 concentrations tested in duplicate.